Saad Sheikh
Overview
Explore the profile of Saad Sheikh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheikh S, Bruno D, Sun Y, Deng V, McClelland 3rd S, Obi E, et al.
J Cancer Educ
. 2024 Apr;
39(5):567-572.
PMID: 38637443
Knowledge related to how oncology treatment trial design influences enrollment of racial and ethnic minorities is limited. Rigorous identification of clinical trial design parameters that associate favorably with minority accrual...
2.
Gross A, Sheikh S, Kharouta M, Chaung K, Choi S, Margevicius S, et al.
Clin Lung Cancer
. 2023 Nov;
24(8):696-705.
PMID: 37993218
Introduction: Extensive-stage small-cell lung cancer (ES-SCLC) continues to have poor survival due to its aggressive behavior, despite improvements with incorporation of immunotherapy with standard chemotherapy. Controversy exists regarding the role...
3.
Sheikh S, Kharouta M, Pidikiti R, DAmico N, Choi S, Dorth J, et al.
Am J Clin Oncol
. 2022 Jan;
45(2):81-87.
PMID: 35073281
Objective: Locally advanced tumors of the head and neck region often lie in close proximity to critical organs at risk (OARs). Providing effective treatment coverage to these malignancies while minimizing...
4.
Sheikh S, Chen H, Sahgal A, Poon I, Erler D, Badellino S, et al.
Radiother Oncol
. 2021 Dec;
167:187-194.
PMID: 34952002
Purpose: In recent years, stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for oligometastatic cancers. Here, we report radiation treatment parameters and clinical outcomes for patients with oligometastatic...
5.
Shamp S, Sheikh S, Chang T, Damico N, Linden P, Dowlati A, et al.
J Radiosurg SBRT
. 2021 Oct;
7(4):271-277.
PMID: 34631228
Purpose/objectives: Outcomes of T2N0 lung cancer patients treated with stereotactic radiotherapy are not well known. Methods And Materials: We conducted a single institution retrospective review of patients with T2N0 NSCLC...
6.
Bouche M, Dong Y, Sheikh S, Taing K, Saxena D, Hsu J, et al.
ACS Biomater Sci Eng
. 2021 Jun;
7(7):3209-3220.
PMID: 34160196
Successful treatment of glioblastoma (GBM) is hampered by primary tumor recurrence after surgical resection and poor prognosis, despite adjuvant radiotherapy and chemotherapy. In search of improved outcomes for this disease,...
7.
Sheikh S, Dey A, Datta S, Podder T, Jindal C, Dowlati A, et al.
Future Oncol
. 2021 May;
17(21):2713-2724.
PMID: 33960209
The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients...
8.
Teng C, Amirshaghaghi A, Cho S, Cai S, De Ravin E, Singh Y, et al.
J Neurooncol
. 2020 Sep;
149(2):243-252.
PMID: 32914293
Introduction: Glioblastoma multiforme (GBM) is the most common primary intracranial malignancy; survival can be improved by maximizing the extent-of-resection. Methods: A near-infrared fluorophore (Indocyanine-Green, ICG) was combined with a photosensitizer...
9.
Cho S, Sheikh S, Teng C, Georges J, Yang A, De Ravin E, et al.
Mol Imaging Biol
. 2020 Jun;
22(5):1266-1279.
PMID: 32514886
Purpose: Fluorescence-guided-surgery offers intraoperative visualization of neoplastic tissue. Delta-aminolevulinic acid (5-ALA), which targets enzymatic abnormality in neoplastic cells, is the only approved agent for fluorescence-guided neurosurgery. More recently, we described...
10.
Jacob F, Salinas R, Zhang D, Nguyen P, Schnoll J, Wong S, et al.
Cell
. 2019 Dec;
180(1):188-204.e22.
PMID: 31883794
Glioblastomas exhibit vast inter- and intra-tumoral heterogeneity, complicating the development of effective therapeutic strategies. Current in vitro models are limited in preserving the cellular and mutational diversity of parental tumors...